Experimental drug shows promise as Alzheimer's target, study says

04/3/2012 | Yahoo!

A study in the Archives of Neurology found the experimental drug bapineuzumab reduces levels of phosphorylated tau in spinal fluid, suggesting it might do the same in the brain and affect tangles associated with Alzheimer's disease. Alzheimer's disease experts who commented on the University of Gothenburg preliminary study said it was too soon to draw any conclusions about whether the drug could stop or even slow the degenerative process of Alzheimer's disease.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY